Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

CStone, the drug’s developer, previously announced similar deals with various pharmaceutical companies to expand sugemalimab ...

Health In Tech announced new partnerships that it says will allow it to introduce a new self-funded health plan. 1 The ...

Paul Howe, chief commercial officer at Protega Pharma, discusses how regulatory agencies are updating their policies based on the presence of abuse-deterrent medications.